Aldehyde oxidase (AOX) is a member of the molybdenum iron-sulfur flavoproteins and is of interest for its role in clinical drug metabolism and as a source of reactive oxygen species (ROS) potentially involved in human pathology. The ROS derived from AOX contribute significantly to alcohol-indu ced hepatotoxic ity. Therefore, expression of AOX could determine both the susceptibility of certain cells and tissues to clinically important pharmacologic agents and the levels of ROS produced under certain pathophysio logical conditions. Although some pharmacologic agents regulate AOX enzyme activity, very little is known about the activation or regulation of the human AOX gene (hAOX). In the present study, we sought to identify features in the upstream DNA of hAOX that could confer regulation of the gene, to locate and characterize the basal promoter apparatus activating hAOX, and to identify transcription factors that could mediate activation or regulation. We transfected promoter fusion constructs into epithelial cells from the lung and the mammary gland that express AOX in cell culture. The hAOX gene was found to possess a structurally complex region in the upstream DNA that contained sequences for a proximal promoter, enhancer sites, and silencer elements. In addition, we identified an essential role for the transcription factors Sp1 and Sp3 in the proximal promoter. Unexpectedly, hAOX was activated in lung and mammary epithelial cells by indistinguishable mechanisms. These observations reveal a potentially complex mode of hAOX gene expression in epithelial cells that is dependent on Sp1 and Sp3 transcription factors. 459 
INTRODUCTION

A
LD EH Y D E O X ID A S E (AOX) is a member of the xanthine oxidase family of molybdenum cofactor-containin g enzymes that includes AOX, several aldehyde oxidoreductases (AOR), xanthine oxidase (XO), and xanthine dehydrogenase (XDH). Vertebrate AOX can be prepared in its native state as a homodim er of 300 kDa, and the 150-kDa monomeric subunits contain two iron-sulfur centers, an FAD, and the molybdenum-pterin cofactor (MoCo) (Hille and Massey, 1985; Wooton et al., 1991; Kisker et al., 1997) . The AOX (EC 1.2.3.1) functions metabolically to catalyze the oxidation of several aldehydes to their cognate acids via hydroxyl transfer from water. While acetaldehyde is an important physiologic substrate for AOX, purines (Krenitsky et al., 1972) , quinoliniums (Taylor et al., 1984) , phthalazines (Beedham et al., 1995) , and numerous pharmacologic agents that include tamoxifen (Ruenitz and Bai, 1995) , famciclovir (Clarke et al., 1995; Rashidi et al., 1997) , zonisamide (Sugihara et al., 1996) , methotrexate (Fabre et al., 1986) , and nicotine (Nakayama et al., 1987) are also important substrates. For example, AOX catalyzes an essential step in the activation of the breast cancer drug, tamoxifen (Ruenitz and Bai, 1995) . The enzyme may also serve an important role in development by the synthesis of retinoic acid from retinal (Huang et al., 1999) .
Aldehyde oxidase is of further interest as a source of the reactive oxygen species (ROS), hydrogen peroxide (H 2 O 2 ) and superoxide anion (O 2 . 2 ), that mediate num erous hum an pathologies and may serve as intracellular signals during oxidative or reductive stress. The ROS derived from AOX are directly implicated in free radical damage to the liver and brain during ethanol metabolism Jayatilleke, 1990, 1992a,b; Shaw et al., 1995; Bondy and Orozco, 1994) . Ethanoldependent ROS generation by AOX could proceed by metabolism of acetaldehyde or NADH, both of which are produced from ethanol by the action of alcohol dehydrogenase (ADH). Because acetaldehyde is a substance for AOX, ROS generation by AOX during acetaldehyde metabolism could be a significant source of ROS in certain tissues. The intrinsic NADH oxidase activity of AOX also generates ROS (Mira et al., 1995; Wright et al., 1995a) . Recently, the ROS injury sustained during alcohol toxicity of the liver was shown to operate directly through the combined activities of AOX and XDH Jayatilleke, 1990, 1992a,b; Mira et al., 1995) via an iron-dependent process that suggests a role for hydroxyl radical ( . OH) in tissue damage (Shaw and Jayatilleke, 1992a; Shaw et al., 1995) .
The AOX genes and cDNAs from several vertebrates have been cloned and analyzed. Hepatic AOX appears to be encoded by a predominantly expressed gene in rats and humans (Wright et al., 1997 (Wright et al., , 1999 Terao et al., 1998) . Sequence variants for hepatic AOX have been described (Wright et al., 1997) , but these have not been fully characterized. The human AOX gene (hAOX) encoding the predominant mRNA in the liver was mapped to chromosome 2q32.3-2a33.1 by fluorescence in situ hybridization (Berger et al., 1995; Wright et al., 1995b) , while rat AOX was mapped genetically to chromosome 9 (Kunieda et al., 1999) . Mouse AOX was mapped to chromosome 1 in a region highly syntenic to human chromosome 2a32-2a33 and rat chromosome 9 (Holmes, 1979) . Mammalian AOXs are encoded by mRNAs of 4700 to 5100 nt, depending on species (Huang et al., 1999; Wright et al., 1995b Wright et al., , 1999 Calzi et al., 1995) , although additional homologous RNAs have been observed in poly(A 1 ) RNA from several rat and human tissues (Wright et al., 1995b (Wright et al., , 1999 .
The hAOX gene lacks an evident TATA sequence in the upstream DNA (Wright et al., 1997; Terao et al., 1998) , and the transcription initiation site found in human liver (Wright et al., 1995b) occurs at a consensus transcriptional initiator (Inr) for mammalian RNA polymerase II, consistent with other TATAless genes (Javahery et al., 1994) . In human liver, the transcription initiation site lies 298 bp upstream of the ATG encoding translation initiation (Wright et al., 1995b) , whereas initiation of transcription in cultured HepG2 cells appear to arise from several sites much closer to the translation initiator (Terao et al., 1998) .
In contrast to the extensive literature surrounding expression and regulation of XDH, very little is known about the expression and regulation of AOX genes. The gene is regulated by tissue type in hum ans (Wright et al., 1995b) , cattle (Calzi et al., 1995) , rabbits (Huang et al., 1999) , and rats (Wright et al., 1999) , with the liver and the lung being the predominant sites of expression. Kidney, pancreas, ovary, prostate, and testes also express AOX. The gene is selectively expressed in human spinal cord microglial cells (Berger et al., 1995) and in some neurons of the mouse brain (Bendotti et al., 1997) . Expression has not been detected in heart or skeletal muscle (Huang et al., 1999; Wright et al., 1995b; Calzi et al., 1995) . Antigen for AOX was reported to exist in several rodent organs, where it appeared to be localized to the epithelial cells in most of the tissues examined (Moriwaki et al., 1996) . Initial analyses of the hAOX gene revealed that promoter inform ation exists in the upstream 1500 bp of DNA and that this region can bind transcription factors determining cell-or tissue-specific expression (Wright et al., 1997; Terao et al., 1998) .
Because expression of AOX could determine both the susceptibility of certain cells and tissues to clinically important pharmacologic agents and the amounts of ROS produced in specific tissues under certain pathophysiologica l conditions, it is important to understand the mechanism by which AOX genes are expressed and regulated. As an initial step in this analysis, we undertook the present study to identify those features in the upstream DNA of hAOX that could confer regulation, to locate and characterize the basal prom oter apparatus activating hAOX, and to identify transcription factors that could mediate expression or regulation.
MATERIALS AND METHODS
Materials and reagents
Media for cell culture were obtained in powdered form from GIBCO/BRL (Bethesda, MD). Antibodies to Sp family members were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Oligonucleotides were synthesized by GIBCO/BRL or Integrated DNA Technology (Coralville, IA). Luciferase fusion plasm ids and the b -galactosidase expression plasmid were obtained from Promega (Madison, WI). The Topo-II T:A cloning vector was obtained from Invitrogen (Carlsbad, CA). O-Nitrophenyl beta-D galactopyranoside, poly dI:dC, and restriction endonucleases were obtained from Roche Molecular Biochemicals (Indianapolis, IN). Most buffers, reagents, and electrophoresis supplies were obtained from Sigma (St. Louis, MO).
Cell culture and transfection
Prelim inary experiments were conducted to identify cells expressing AOX in culture. Because AOX appears to be expressed largely by epithelial cells in vivo, we examined numerous cultured epithelial cells from many different organs using an RT-PCR expression assay. The MLE-15 lung epithelial cells (Wikenheiser et al., 1993) and HC-11 mammary gland epithelial cells (Hynes et al., 1990) were found to express AOX. The former were grown in modified HITES medium containing RPMI 1640, 3 mM L -glutamine, sodium bicarbonate (2 g/l, pH 7.4; 13 Sigma ITS liquid media supplement (insulin, transferrin, sodium selenite), bovine transferrin 2.5 mg/l, 5 nM hydrocortisone, 5 nM beta-estradiol, 5 mM HEPES, pH 7.4; 13 GIBCO/BRL antibiotic-antimy cotic (penicillin G 100 units/ml, streptomycin sulfate 100 m g/ml, amphotericin B 250 ng/ml), and fetal bovine serum to 2%. The HC-11 cells were grown in RPMI 1640 containing 2 mM L-glutam ine, sodium bicarbonate 2 g/l, pH 7.4; 13 antibiotic/ antim ycotic, insulin 5 m g/ml, epidermal growth factor 10 ng/ml, and 10% fetal bovine serum . Cells were maintained at 37°C in 95% air/5% CO 2 and were refed every 2 days and split 1:6 when at or near confluency.
Cells to be transfected were grown to 50% to 70% confluency in six-well plates. Transfections were conducted using the liposome vehicle Transfectam (Promega) essentially as described by the supplier. Test plasm id (5.0 m g) and 1.0 m g of pCMV b -galactosidase plasmid were mixed with Transfectam in 1.0 ml of RPMI 1640/ sodium bicarbonate medium (starvation medium). After vortexing, the transfecting solution was applied to cells in two wells of a six-well plate for 2 h. Then, either complete medium or starvation medium was applied without rem oval of the transfecting solution. Cells were harvested for analysis after 48 h of incubation. Wells were harvested in pairs and analyzed for luciferase activity (Promega CCLR kit) using a BMG Lab Technologies (Durham, NC) Lumistar lum inom eter. b -Galactosidase activity was assayed by reduction of o-nitrophenyl b -D-galactopyranosid e and followed spectrophotome trically at 420 nm. The protein content was determined spectrophotome trically using the Lowry assay. 
Construction of AOX promoter/luciferase fusions and upstream deletions
Twelve in frame fusions with the luciferase coding region were constructed exactly as indicated previously (Wright et al., 1997) for both the pGL3-basic (pGL3-B) and pGL3-enhancer (pGL3-E) parent plasm ids (Promega). Briefly, upstream DNA to be cloned in the pGL3 plasmids was amplified by PCR using the PAC 8300 artificial chromosom e as a template. The 39 mutagenic oligonucleotide (AOXCON: 59 -GCAGCTGCCCACGCCCGGTCCATGgGGTGTCCGCGCTGG-39 ) was designed to convert the AOX initiating ATG into an Nco1 restriction endonuclease cleavage site by changing a single A at 2 1 to a C (at the base indicated in lowercase). The 59 PCR oligonucleotide was derived from the upstream DNA sequence (GenBank Accession No. AF010260) and could be cloned at a blunt cloning site in each vector (Sma1). We reported 1500 bp of the AOX upstream DNA sequence in 1997 but have extended this to more than 2600 bp, as described in the GenBank data base. Figure 1 shows the series of upstream deletion constructs. The A residue of the luciferase initiating ATG is denoted by 1 1, and all upstream nucleotides are numbered from this site with a negative number. For each reporter plasmid, PCR products were cleaved with Nco1 and purified by agarose gel electrophoresis. Bands of the appropriate size were extracted in phenol, precipitated in ethanol, and reconstituted in TE buffer. Host plasm ids, pGL3-E or pGL3-B, were cleaved with the restriction endonucleases Nco1 and Sma1, after which they were likewise purified by agarose gel electrophoresis. Recombinants were constructed by overnight ligation at 12°C in a 20-m l volume and were transformed into SURE cells (Stratagene, La Jolla, CA). Ampicillin-resistant colonies were screened for the appropriate recombinant using colony PCR amplification. Plasmid DNA was prepared from positive colonies by the alkaline lysis method. Recombinant plasmids were confirmed to contain a single copy of the appropriate upstream fragment by a com bination of DNA sequence analysis and restriction endonuclease cleavage analysis with Nco1 and Kpn1. The latter was selected as the second diagnostic enzyme because the Kpn1 site lies within the multicloning site of each parent plasmid upstream of Sma1. The presence of a single Kpn1 site in the AOX upstream DNA at 2 1533 bp provided an additional diagnostic cleavage site for longer constructs. Preliminary experiments revealed weak expression of the hAOX promoter in the B series of constructs; therefore, the E series of constructs were used to determine the primary characteristics of the hAOX upstream DNA.
DNA sequence analysis
Fluorescence sequence analysis was perform ed using the dideoxynucleotide chain termination system from Perkin-Elmer Applied Biosystem s (Foster City, CA). Reactions used the ABI PRISM™ Dye Terminator cycle sequencing ready reaction kits (Perkin-Elme r). Sequence reactions were fractionated on an ABI PRISM 310 DNA sequencer equipped with a 47-cm microcapillary (Perkin-Elme r). All sequences were determined from both directions, and sequence data were compiled manually. The oligonucleotides used as sequencing primers are available on request.
RNA initiation site
Total RNA was prepared from cultured cells grown to 80%/90% confluency using the Trizol reagent (Life Technologies). The MLE-15 and HC-11 cells were shown to express AOX in cell culture by RT-PCR as follows. All RNA sam ples were treated with DNase I prior to cDNA synthesis. cDNA was prepared by reverse transcription (RT) . Reaction mixtures were incubated at 42°C for 60 min and were then heated to 94°C for 5 min to inactivate reverse transcriptase. Prior to use, reactions were diluted to 100 m l, and 5 m l was used for PCR amplification. The RT reaction mixtures were stored at 2 70°C. Semiquantitative PCRs were determ ined to be in the linear range of AOX and b -actin product formation for input RNA, input single-strand RT DNA, and the number of amplification cycles. The 59 RACE was then used to determine the RNA initiation site employed by the AOX-luciferase fusion genes in culture cells. The HC-11 and MLE-15 cells were transfected with pAO-E4, and RNA was harvested 48 h later. The 59 RACE was perform ed on total RNA as described previously (Wright et al., 1999) using ALSS-DNA and a primer extension oligonucleotide derived from the luciferase proteincoding region.
Preparation of probes for electrophoretic mobility shift assays
The 2 1/2 167-bp probe corresponding to the hAOX proximal promoter (Fig. 2 ) was prepared from pAO-E1 by restriction endonuclease cleavage with Nco1 and Kpn1. The appropriate fragment was purified by agarose gel electrophoresis. DNA fragment (500 ng) was end-labeled with bacteriophage T4 DNA polymerase for 5 min at 37°C in a 50-m l reaction mixture containing 50 m Ci [a -
32 P]-dATP; 2 U of T4 DNA polymerase; 500 m M dCTP, dTTP, dGTP; 50 mM Tris, pH 8.0; 5 mM MgCl 2 , and 5 mM dithiothreitol (DTT). Probe was extracted in (24:24:1) phenol:chloroform :isoamyl alcohol, precipitated in ethanol, and resuspended in TE at 0.5 ng/m l. Double-strand oligonucleotide probes (60 ng) were labeled with 50 m Ci of [g -32 P]-ATP by polynucleotide kinase according to the manufacturer' s specifications (Roche). Probes were extracted, precipitated, and stored until use at 0.5 ng/m l in TE as described above.
Preparation of nuclei and nuclear proteins
Nuclei were prepared from hypotonically swollen cells by douncing and differential centrifugation following standard methods (Dignam et al., 1983) . Proteins were leached from isolated washed nuclei by incubation in 320 mM potassium buffer as described (Dignam et al., 1983) . Nuclear preparations were routinely exam ined microscopically and were estimated to contain . 95% nuclei with no more than 5% cellular contamination. Following sedimentation at 10,000 3 g to rem ove extracted nuclei, protein solutions were stored at 2 70°C in high-salt buffer containing 20 mM HEPES, pH 7.9; 1.5 mM MgCl 2 , 320 mM KCl, 0.2 mM EDTA, 0.2 mM phenylm ethylsulfonylfluoride, 0.5 mM DTT, and 25% glycerol.
Electrophoretic mobility shift analysis
The 50-m l EMSA binding reactions without competitors contained 17.8 m g of nuclear protein, 5 m g of poly dI:dC, 0.5 ng of labeled probe, and final reaction buffer composed of 25 mM Tris, pH 7.9; 50 mM KCl, 6.25 mM MgCl 2 , 0.5 mM DTT, 0.5 mM EDTA, and 10% glycerol. Double-stranded oligonu-WRIGHT ET AL. 462
FIG. 1.
The hAOX promoter-luciferase fusions. Upstream DNA from the hAOX gene cloned in PAC 8300 was fused at the initiator methionine of the pGL3-enhanc er (pGL3-E) plasmid using the mutagenic oligonucleotide AOXCON to convert the ATG into an Nco1 cleavage site. All fusions, therefore, precisely fuse DNA upstream of the AOX ATG with the luciferase ATG. Numbering of upstream DNA begins with the first base 59 of the AOX ATG as 2 1, and the 59 base of each fusion is listed at the left of each construct. Plasmid pGL3-E is the promoterless parent vector and contains an SV40 enhancer located 39 of the luciferase gene. Fusions containing sequences that extend up to 2 kb into intron 1 produced diminished activation and have been excluded from the present study.
cleotide competitors were included at 20-, 50-, or 100-fold molar excess as indicated in the figures. Supershift experiments with antisera to Sp1, Sp2, or Sp3 were conducted at a 19.6:1 dilution of antiserum. Preimmune sera were not employed in the present studies because the complete absence of response to the anti-Sp2 antiserum provided an effective nonspecific control. Binding reactions were assembled in the following order: H 2 O, buffer, nuclear protein solution, poly dI:dC, competitor oligonucleotide, and labeled probe. Antisera to Sp1, Sp2, or Sp3 were added either 5 min before probe addition or at the end of the binding reaction, 5 min prior to electrophoresis. Binding reactions were conducted at room tem perature for 30 min. Following addition of Ficoll dye, 10 m l of binding reaction mixture was electrophoresed on 4% native polyacrylamide gels at 125 V for approximately 4 h. The gels were subsequently dried and exposed to Kodak XAR autoradiographic film.
Competitor oligonucleotides were derived from the hAOX proximal promoter (Fig. 2) and correspond to the TTF-1, STAT, and Sp1wt binding sites (Fig. 3) . Substitution oligonucleotides were derived from the hAOX Sp1wt binding region. Substitutions of the wildtype sequence were made three at a time, span the entire 30 bp of the wildtype sequence and correspond to Sp1a through Sp1j (Fig. 3) . The altered triad in each oligonucleotide is underlined. The Sp1 substitution oligonucleotides were used both as competitor oligonucleotides and as individual probes. The B-region substitution oligonucleotides Sp1k and Sp1l were derived from the Sp1wt2 oligonucleotide (Fig.  3 ) that is shifted 6 bp 39 relative to Sp1wt.
Construction recombinant plasmids containing Sp1/Sp3 mutations
Substitution mutations were introduced into the Sp1/Sp3 A and B domains of pAO-E1 and pAO-E4 by cassette mutagenesis. Because of constraints in cloning into the pAO-E series of plasmids, the six core nucleotides of each domain were replaced by an Nde1 cleavage site that changed the core Sp1 nucleotides from CGCCCC to CATATG (A domain) and GGTGCC to CATATG (B domain). Parent plasmids pAO-E1 and pAO-E4 were amplified by PCR in two separate reactions using Nde1 mutagenic primers paired with flanking primers derived from the pGL3-E host vector. DNA fragm ents of the appropriate size were isolated by gel electrophoresis and cloned in the Topo-II T:A cloning vector (Invitrogen). The resulting clones were cleaved with Nde1 and either Kpn1 (upstream fragment) or Apa1 (downstream fragment). The Nde1/Apa1 and Nde1/Kpn1 fragm ents were ligated, subcloned into Topo-II, and sequenced to confirm the anticipated structure. Subsequently, Kpn1/Apa1 fragm ents corresponding to domain A or dom ain B Nde1 substitutions were isolated by gel electrophoresis. The parent plasmids, pAO-E1 and pAO-E4, were cleaved with Kpn1 and Apa1 and gel purified to isolate hosts lacking the region from the Kpn1 site to the Apa1 site. The Kpn1/Apa1 fragments contain-HUMAN ALDEHYDE OXIDASE PROMOTER 463
FIG. 2.
Sequence features of the hAOX proximal promoter. Upstream sequence and sequence of the coding region to intron 1 is shown by uppercase letters. Lowercase letters show the first bases of intron 1 (Wright et al., 1997) . Computer-pred icted transcription factor binding sites have been identified using the program TRANSFAC, and the core binding domains are underlined. Only those sites showing . 95% probability for transcription factor prediction have been indicated.
FIG. 3.
Oligonucleotides used in the analysis of the hAOX proximal prom oter. Only the upper strand of each oligonucleotide is shown. The STAT, TTF-1, and Sp1 sequences were derived from the hAOX proximal promoter; Sp1a through Sp1j contain 3-bp substitutions of the wildtype Sp1wt region in hAOX, and these are underlined. The Sp1wt2 oligonucleotide is translocated by 6 nt (39 ) relative to Sp1wt. Both Sp1k and Sp1l contain substitutions of Sp1wt2 indicated by the underline. ing the Nde1 substitution were then cloned into each deleted parent, creating the substitution mutations M1 (corresponding to the A domain) and M2 (corresponding to the B domain). Thus, four substitution plasmids were generated (pAOE1-M1, pAOE1-M2, pAOE4-M1, and pAOE4-M2), each carrying the substitution CATATG in place of the core Sp1/Sp3 hexanucleotide. The proper structure of each substitution mutation was confirmed by sequence analysis.
Construction of silencer recombinant plasmids
The strong silencer domain lying from 2 1978 to 2 2230 was subcloned in the forward direction into four promoter plasmids as follows. The PAC 8300 artificial chrom osome containing the 77,000-bp hAOX and upstream DNA (Wright et al., 1997) was amplified using the primers PRO18K (59 -ACACAGGTACC-CCTCCTGCCCTGGCCCGTTTTCTCTCC-39 ) and PRO17N ( 5 9 -A A C A C A G C T A G C C C A T C T A G G T G G A A T A -GAGTTTGAG-39 ) that carry, respectively, a Kpn1 or an Nhe1 restriction endonuclease cleavage site (boldface). A PCR band of approxim ately 275 bp was obtained and was cleaved sequentially with Kpn1 and Nhe1; the product was isolated by agarose gel electrophoresis. Recipient plasmids consisted of pGL3-promoter, pGL3-control, pAO-B1, and pAO-E1. Following sequential cleavage with Kpn1 and Nhe1, the plasmids were purified by agarose gel electrophoresis. Recombinants were ligated overnight and transformed into SURE cells. Positive colonies were identified by PCR colony screen to ensure that only clones with a single insert in the forward orientation were obtained. Correct cloning was confirmed by a combination of DNA sequence analysis and restriction endonuclease cleavage analysis with Kpn1, Nhe1, and Nco1.
RESULTS
Complex architecture of the hAOX upstream DNA
We found that several cultured epithelial cells would express AOX, including MLE-15 lung epithelial cells and HC-11 mammary gland epithelial cells. Therefore, expression of luciferase from the plasmids pAO-B4, pAO-E4 (with the 59 terminus at 2 930), pAO-B12, and pAO-E12 (with the 59 terminus at 2 2607) was tested in MLE-15 and HC-11 cells. The MLE-15 cells have been stably transfected with SV40 large T antigen and should greatly stimulate E-series plasmids, whereas HC-11 cells do not express T antigen. The pGL3-B series of enhancerless plasmids exhibited very low expression in both cell types (data not shown), while the presence of an SV40 39 enhancer in the pGL3-E series of plasmids markedly stimulated expression in both cell types. Furthermore, the additional DNA present in pAO-B12 and pAO-E12, rather than stimulating expression relative to pAO-B4 and pAO-E4, resulted in diminished activity in both cell types. Further experiments were conducted in the E series of plasmids because we could not detect expression from pAO-B12 in either cell type.
The E series luciferase fusion plasmids pAO-E1 through pAO-E12 and the promoterless parent pGL3-E were transfected into MLE-15 and HC-11 cells. The increased luciferase activity observed in MLE-15 cells com pared with HC-11 cells was preserved throughout the entire 2607 bp of upstream DNA (Fig.   4A ). When luciferase data were normalized to the promoterless parent, pGL3-E, the pattern of activation was essentially identical in the two cell types (Fig. 4B) . Several functional dom ains were identified in the hAOX upstream region. First, negativeacting sequences were found from 2 1288 to 2 1505 and from 1978 to 2 2230, with the latter being much more suppressive than the form er. Importantly, the addition of sequences 59 of 2 2230 restored expression to a fusion plasmid terminating at 2 2230, as can be seen for clones pAO-E11 and pAO-E12 that terminate, respectively, at 2 2441 and 2 2607 (Fig. 4) . Second, a strongly positive-acting site was found from 2 609 to 2 930 that may represent an upstream enhancer. Third, little change in basal activation in either cell type was found between 2 167 and 2 609. Regardless of cell type, the region from 2 1 to 2 167 induced 15-to 20-fold activation over the promoterless parent (pGL3-E) that was not statistically different for pAO-E1, pAO-E2, or pAO-E3. Therefore, the 2 1/2 167 region must contain sufficient information to comprise a proximal promoter. Deletions were not constructed 39 of 2 167 in order to preserve a potential TTF-1 binding site (see Fig. 2 ) that was expected to be functional in MLE-15 lung cells but not in HC-11 mammary gland cells.
Identification of an hAOX proximal promoter
We had identified a single predominant site for transcription initiation in normal hum an liver (Wright et al., 1995b ) that lies 298 bp upstream of the AOX ATG at a consensus Inr (Javahery et al., 1994) . However, in cultured HepG2 liver cells, RNA appeared to initiate from two dominant sites at 2 49 and 2 56 (Terao et al., 1998) . Because the 2 1/2 167 region supported efficient expression of luciferase in HC-11 and MLE-15 cells, we anticipated that the proximal sites would also be functional in these cells. We performed 59 RACE on total RNA from HC-11 and MLE-15 cells transfected with pAO-E4 (59 terminus at 2 930) using an oligonucleotide derived from the luciferase coding region to prime RT. Thus, only RNA derived from the fusion plasm id would be copied. A single major band was obtained and was sequenced to locate the 59 nucleotide. This sequence was 59 -CCCTCGAACCAGCGCGGACACCAC-CATGG-39 , placing the initiation site used by the fusion plasmids exactly 25 nt upstream of the ATG for translation initiation in both cell lines.
The same transcription factors were determined to bind in the hAOX proximal promoter in lung and mammary gland epithelial cells. Nuclear protein complexes from MLE-15 and HC-11 cells that formed with the hAOX proximal promoter were indistinguishable when examined by EMSA. Nuclear proteins from each cell produced three complexes with identical mobility in the two cell types (complexes CI, CII, and CIII; Fig. 5 ). Complexes CI, CII, and CIII were all efficiently blocked by a 100-fold and 50-fold molar excess of either the unlabeled 2 1/2 167 probe itself or the Sp1 region oligonucleotide. Neither the TTF-1 nor the STAT factor oligonucleotide was an effective cold competitor. Cold competition with the Sp1 domain oligonucleotide generated equivalent and simultaneous competition for all three complexes regardless of cell type (Fig. 5A, B) .
Antisera against Sp1, Sp2, and Sp3 were employed in EMSA supershift experiments (Fig. 5C, D) . Antisera against Sp1 appeared to exert two effects on complexes from both cell types:
FIG. 4.
Complex architecture of the upstream region of hAOX. Each of the 12 E-series luciferase fusion plasmids and the parent plasmid, pGL3-E were transfected into MLE-15 and HC-11 cells along with pCMV-b -galactosidase. After 48 h, luciferase activity was determined and normalized to b -galactosidase and protein concentration (A). Each transfection was analyzed four times, and five repetitions of the entire transfecting series were performed; thus, each point represents 20 individual assays. Error bars show the standard deviation of the entire 20 assays. (B) Data for each transfecting plasmid were then normalized to pGL3-E to determine the degree of stimulation beyond the promoterless parent. Luciferase activity for pAO-E10 (59 terminus at 2 2230) was consistently at or below activity of pGL3-E. Site of 59 terminus identifies the 59 nucleotide of the deletion (see Fig. 1). 
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CII was com pletely lost, and CI was reduced to approximately 50% of the original band intensity. Antisera against Sp2 exerted no detectable effect on any of these complexes and were hereafter used as a control for nonspecific effects of the antisera. Antisera against Sp3 completely abrogated formation of CI and CII regardless of cell type. The minimal interpretation of these data is that CIII contains Sp3 and not Sp1, CII contains Sp1 and not Sp3, and CI contains Sp3 and perhaps Sp1. Although the binding of additional proteins is not precluded by these observations, Sp1 and Sp3 binding are required for complex formation, as just described.
While all nuclear protein binding in the proxim al prom oter was efficiently and completel y blocked by the Sp1 dom ain oligonucleo tide alone, both Sp1 and Sp3 were required to form the three com plexes detected in the hAOX proxim al prom oter. Furtherm ore, inspection of the Sp1 domain oligonucleo tide sequence indicated the presence of two Sp1-relate d sequences, suggesting that Sp1 or Sp3 could bind to more than one site. As was observed for the 167-bp proxim al promoter, three com plexes were form ed by using the Sp1 domain oligonucleotide as a probe in EMSA analysis, complexes CIV, CV, and CVI, in both MLE-15 and HC-11 cells (Fig. 6) . The CV appeared to possess approxim ately twice the band intensity of CVI. However, by running the PAGE for a longer time, CIV could be clearly separated from CV. All three complexes were com pletely and efficiently blocked by a 100-fold-or 50-fold excess of cold Sp1 domain oligonucleo tide. Antisera to Sp1 eliminated the formation of CIV and may have diminished CV by 50% . Antisera to Sp2 had no detectable effect on complex formation. Antisera to Sp3 precluded form ation of both CV and CVI without affecting CIV. These data indicate that CIV contains Sp1 and not Sp3, CV contains Sp3 and may contain Sp1, while CVI contains Sp3 and not Sp1. As noted previously, the binding of additional proteins is not precluded by these data. In addition, neither the STAT nor the TTF-1 domain oligonucleo tide produced detectable binding of either MLE-15 or HC-11 nuclear proteins when used as an EMSA probe. 
WRIGHT ET
Sp1 and Sp3 bind at two adjacent sites in the hAOX proximal promoter
To determine how Sp1 and Sp3 bound in the hAOX proximal promoter, substitutions were introduced into the Sp1 domain oligonucleotide, 3 nt at a time and spanning the entire oligonucleotide. Modified oligonucleotides Sp1a through Sp1j were used as cold competitors in EMSA with the 2 1/2 167 probe. In both MLE-15 and HC-11 cells, com petition failed in two sites of 6 nt each (Fig. 7A, B) . The Sp1e and Sp1f defined binding domain A, in which cold competition failed completely for CI, CII, and CIII simultaneously. The Sp1i and Sp1j form ed dom ain B, in which com petition also failed simultaneously for CI, CII, and CIII. Substitutions at Sp1a, Sp1b, Sp1g, and Sp1h had essentially no effect on competition efficiency. The Sp1c and Sp1d exhibited some dim inished competition efficiency. However, domains A and B appeared to be important simultaneously to the form ation of all three complexes. Analogous data were obtained in both MLE-15 and HC-11 cells when using the Sp1 dom ain oligonucleotide as a probe (Fig. 7C, D) . The Sp1e and Sp1f produced very poor competition, and Sp1i and Sp1j were inefficient competitors. As with the 2 1/2 167 EMSA probe, all complexes formed with the Sp1 dom ain, oligonucleotide probe (Fig. 7C, D ) failed simultaneously and with equivalent efficiency, despite being separated by 9 to 12 nt. For example, the 3-nt substitutions at Sp1f produced an oligonucleotide with essentially no competitive value for Sp1-or Sp3-containing complexes, and markedly reduced competitive value was obtained with Sp1j as well. These data strongly indicate the cooperative nature of binding of both Sp1 and Sp3 to the hAOX proxim al prom oter.
We corroborated these observations by using each substitution oligonucleotide as a probe in EMSA analysis (Fig. 8) . In this case, substitutions at Sp1e and Sp1f or Sp1i and Sp1j resulted in failure or diminished capacity of the oligonucleotide to form either Sp1-or Sp3-containing complexes. The CIV, CV, and CVI all failed to form with equivalent efficiency and simultaneously, regardless of cell type. Furtherm ore, none of the three base substitutions that abrogated Sp1 and Sp3 binding resulted in the formation of any new complexes. Interestingly, substitutions of Sp1b and Sp1g resulted in improved binding of all three complexes. These observations support the significance of domains A and B for Sp1 and Sp3 binding and demonstrate that binding is cooperative.
Refined localization of region B binding
Our data localized Sp1/Sp3 binding to the A and B regions as described above. We suspected that the limits of region B could extend further in the 39 direction and, therefore, conducted additional competition EMSA using nuclear proteins from HC-11 and MLE-15 cells. Competitor oligonucleotides Sp1k and Sp1l carry 3-bp substitutions of the Sp1wt2 oligonucleotide. Each of these three double-stranded competitors has a 59 end exactly 6 bp 39 of the Sp1wt oligonucleotide. Figure  9 shows that substitutions in Sp1k and Sp1l abrogated competitive efficiency relative to Sp1wt2. Thus, region B binding, like region A binding, spans 12 nt, with the most critical sites being the 39 6 nt.
Sp1 and Sp3 are essential for activation of the proximal promoter in hAOX
To determine if the Sp1/Sp3 sites identified in vitro were functional in transfected cultured cells, we cotransfected HC-11 cells with pAO-E1 and double-stranded phosphorothiolat ed oligonucleotides as decoys for the Sp1/Sp3 region. The specific decoy corresponded to Sp1wt, and the nonspecific decoy had a random sequence that produced no identity matches when BLAST analyzed through the NCBI DNA sequence database. Figure 10A show s that the phosphorothiolate derivative of Sp1wt blocked expression from pAO-E1 in concentrations from HUMAN ALDEHYDE OXIDASE PROMOTER 467
FIG. 7. Identification of critical protein-binding domains in the hAOX proximal prom oter. (A, B)
The 2 1/2 167 proximal promoter DNA was used as a probe in competitive EMSA with Sp1-substitution oligonucleotides Sp1a through Sp1j using nuclear proteins from MLE-15 (A) and HC-11 (B) cells. All competitors were present in 50-fold molar excess. The Sp1 domain oligonucleotide was also used as a probe in competitive EMSA (C, D) with Sp1-substitutio n oligonucleotides and nuclear proteins from MLE-15 (C) and HC-11 (D) cells. All competitors were present in 50-fold molar excess. 30 ng/ml to 100 ng/ml, whereas the nonspecific oligonucleotide had little discernible effect on expression. This result indicates that the Sp1wt domain is essential for expression of the proximal promoter in vivo.
To confirm and extend these data, substitution mutations were introduced into pAO-E1 and pAO-E4 by converting domain A and domain B core hexanucleotides into Nde1 restriction sites (Fig. 10B) . In each case, this action resulted in a 5 of 6 nt substitution. The substitutions correspond to changes known to abrogate Sp1 binding and are similar, but not identical, to those used in competitive EMSA. Figure 10C demonstrates that substitution mutagenesis of domain A in both pAO-E1 and pAO-E4 resulted in nearly complete suppression of luciferase expression. Independent domain B mutagenesis decreased expression 40% and 60% in pAO-E1 and pAO-E4, respectively. This finding confirm s that the Sp1/Sp3 sites identified are essential for expression. The M1 mutation was consistently more suppressive than M2, despite their equivalent effect on in vitro protein binding. Figure 11 summarizes the structure of the hAOX proximal promoter as determ ined here.
Identification of an upstream silencer
The strongly negative sequence from 2 1978 to 2 2230 in the hAOX upstream DNA suggested the existence of a silencer element. Sequence analysis revealed no alterations in the hAOX DNA from pAO-E10, indicating that the negative activity of pAO-E10 was not the result of mutation or rearrangement during cloning or PCR amplification. To confirm that the negative activity of this region was not the result of defective cloning at som e site other than in the hAOX DNA, pAO-E10 was cleaved with Kpn1, religated, and cloned. This produced a derivative with the 59 terminus at 2 1524, a site 19 bp 59 of the pAO-E7 59 terminus. Also, pAO-E12 was deleted to 2 2230 using reverse PCR and recloning to reconstruct pAO-E10 from pAO-E12. The reconstructed pAO-E10 produced luciferase activity in MLE-15 and HC-11 that was essentially indistinguishable from that produced by the original pAO-E10. Furthermore, reconstructing pAO-E7 from pAO-E10 also generated a clone that was expressed in both cells with essentially the sam e activity as the original pAO-E7. This result confirmed that the activity of pAO-E10 was not artifactual.
To determine if the region between 2 1978 and 2 2230 would confer repression independently, it was amplified by PCR, cleaved with Kpn1 and Nhe1, and subcloned in the forward direction upstream of promoters in pGL3-promoter, pGL3-control, pAO-B1, and pAO-E1 (Fig. 12, top panel) . the 2 1978 to 2 2230 region repressed activity in each of these clones except the pGL3-promoter plasmid (Fig. 12, bottom panel) . Both pGL3 plasm ids contain an SV40 promoter; they differ from each other by the absence of a 39 enhancer in the pGL3-promoter plasmid. The paradoxical activation seen here with incorporation of the 2 1978/ 2 2230 silencer into the pGL3-promoter is similar to the action of another described silencer that can also serve as an activator depending on its physical location in the reconstructed gene (Shou et al., 1998) . Nonetheless, the ability of the hAOX 2 1978/ 2 2230 region to repress activity when placed 59 of either a foreign promoter or the hAOX proximal promoter identifies the silencer function of this domain. 
DISCUSSION
FIG. 9.
Improved localization of region B binding. The EMSAs were performed using nuclear proteins from MLE-15 (A) and HC-11 (B) cells. Competitor oligonucleotides Sp1wt2, Sp1k, and Sp1l were shifted 6 bp in the 39 direction relative to Sp1wt. All com petitor oligonucleotides were present in 50-fold molar excess of the 2 1/2 167 labeled probe. The Sp1wt2 was a less efficient competitor than Sp1wt, reflecting the minor importance of the first 3 bp of Sp1wt for Sp1/Sp3 binding. This can be seen in the reduced efficiency of competition with Sp1a relative to Sp1wt. from the lung and the mammary gland that express AOX in cell culture, consistent with observations demonstrating epithelial expression in vivo. Second, we identified a structurally complex region in the upstream region of hAOX containing sequences for a proximal promoter, enhancer sites, and a silencer element, indicating the potential for com plex regulation of AOX gene expression. Third, we identified an essential role for the transcription factors Sp1 and Sp3 in the proximal promoter in the activation in epithelial cells. An important conclusion from these studies is that lung and mammary gland cells displayed great similarity in the means of AOX expression and in the involvement of Sp1 and Sp3 transcription factors in the proximal promoter. We observed essentially no difference in expression between lung and mammary gland cells throughout the 2607 bp of upstream DNA studied here. Sites for the proximal promoter, activation, and silencing were located on the sam e 59 deleted clones. The regions between 2 1288 and 2 1505 (pAO-E7) and between 2 1978 and 2 2230 (pAO-E10) behaved as strongly negative sites in both MLE-15 and HC-11 cells. The domain from 2 609 to 2 930 (pAO-E4) behaved as an activation or enhancer region in both cells, and in both cells, little change in expression was detected from 2 167 to 2 609 (pAO-E1, pAO-E2, and pAO-E3).
We identified a proximal promoter in the region from 2 1 to 2 167 bp. Both MLE-15 and HC-11 cells activated the proximal promoter 15 to 20 fold over the parental plasmid. Therefore, the 2 1/2 167 region contains sequences sufficient for basal activation and transcription initiation. We identified a (Terao et al., 1998) . Thus, the selection of proximal transcription initiation sites may reflect a com mon characteristic of cultured cells. Nuclear protein binding in the proxim al promoter did not appear to differ between lung and mammary gland cells. Neither MLE-15 nor HC-11 nuclear proteins revealed binding to the predicted TTF-1 or STAT sites. Instead, Sp1 and Sp3 formed complexes of mobility indistinguishable from that of MLE-15 and HC-11 nuclear proteins. Furthermore, site-directed substitution of the Sp1 domain oligonucleotide revealed the same nucleotides to be essential for Sp1 and Sp3 binding regardless of the cell from which the nuclear proteins were prepared. We draw the unexpected conclusion that lung and mammary gland epithelial cells activate the hAOX proximal promoter in very similar, if not identical ways, and that Sp1 and Sp3 are central to this process.
We had anticipated that transcription factors specific for the lung or the mammary gland would be responsible in part for activation of AOX in epithelial cells from these tissues. For example, TTF-1 is the best-studied transcription factor mediating lung-specific activation, and the hAOX upstream DNA contains sites predicted to bind TTF-1 at 2 1664, 2 1523, 2 1243, 2 957, 2 918, 2 649, and 2 477 and in the proximal promoter at 2 163. These sites match the consensus TTF-1 binding site from a low of 91% identity to a high of 100% identity. The TTF-1 was expected to activate the hAOX proximal promoter in MLE-15 cells but not in HC-11 cells, as the predicted TTF-1 binding site in the proximal prom oter appeared to be quite good (Bruno et al., 1995; Bohinski et al., 1994) . Furthermore, AOX is dramatically expressed in the lungs of several mammals, and TTF-1 is expressed and functional in the MLE-15 cells used here (Ikeda et al., 1996) , whereas it is not expressed in breast epithelia (Holzinger et al., 1996) . However, we found no nuclear protein binding in the predicted TTF-1 region of the hAOX proximal promoter using conditions in which TTF-1 is known to bind in vitro . Thus, TTF-1 does not contribute to activation of the proximal promoter.
Both STAT3 and STAT5 are important mediators of mammary gland developm ent (Philip et al., 1996) . Either STAT3 or STAT5 was expected to activate the hAOX proximal promoter, because this region contained an excellent match for the consensus binding site for STAT factors, and the HC-11 cells expressing the hAOX proximal promoter are mammary gland epithelial cells. Nonetheless, the predicted STAT binding site in the hAOX proxim al promoter did not appear to contribute to nuclear protein binding under the conditions employed in the present study. Other transcription factors with important specific roles in the mammary gland include YY1 (Meier and Groner, 1994) and MGF (Meier and Groner, 1994; Wakao et al., 1994) that may mediate AOX regulation in HC-11 cells outside the proximal promoter.
The Sp1 and Sp3 factors were found to be essential to the formation of all nuclear protein complexes with the hAOX proximal promoter in vitro. Two sites were active in this region, identified as dom ains A and B, lying at 2 96 to 2 101 (A) and 2 78 to 2 83 (B). We observed that binding of Sp factors was cooperative. Independent substitutions in either domain A or domain B resulted in the loss of nuclear protein binding to both sites simultaneously and with equivalent efficiency, whereas substitutions betw een sites did not diminish competition or preclude nuclear protein binding. Thus, domains A and B functioned cooperatively, not independently. The sequence in domain A corresponds to the consensus Sp1 binding site, whereas the sequence of domain B does not. It will be important to determine how Sp1 and Sp3 occupy these sites, as dom ain B may represent a novel binding site perhaps related to cooperative binding. We infer that Sp1 and Sp3 cannot be bound simultaneously in com plexes CII and CIII, because Sp1 antisera did not affect the Sp3 (CIII) complex and Sp3 antisera did not affect the Sp1 complex (CII). Furthermore, domains A and B were shown to be essential for luciferase expression from the fusion plasmids pAO-E1 and pAO-E4 by substitution mutagenesis. Whereas mutations in dom ains A and B behaved essentially the sam e in vitro, in vivo, the dom ain A mutation was more sup- pressive than the domain B mutation. This may result from the differences in the mutations used or may indicate a potential for more complex protein interactions in vivo. In each case, mutations were designed to convert the core Sp1 G:C box into an A:T box consistent with disruption of Sp1 binding (Discher et al., 1998; Hata et al., 1998) . The mutations used in vitro converted each domain into pure A:T sequences, whereas the Nde1 mutations used in vivo carry a C and a G residue in the first and sixth positions. Nonetheless, we conclude that Sp1/Sp3 are the critical transcription factors mediating activation of the hAOX proxim al prom oter.
The Sp1 and Sp3 factors are well known to function jointly in the expression of many genes and in many different cell systems (Rajakum ar et al., 1998; Discher et al., 1998; Hata et al., 1998; Kida et al., 1999) . Thus, Sp1 is frequently found to activate gene expression, whereas Sp3 can function in either activation or repression (Majello et al., 1997; Kennett et al., 1997) . Hence, the relative levels of Sp1 and Sp3 can determine promoter in pGL3-prom oter and pGL3-enhance r; AOX 5 hAOX proximal promoter 2 1/2 167 in pAO-E1 or pAO-B1. P, pGL3-promoter, P 1 10, pGL3-promot er with silencer (2 1978 to 2 2230) inserted upstream of the SV40 promoter; C, pGL3-control ; C 1 10, pGL3-control with the silencer domain inserted upstream of the SV40 promoter, B1, pAO-B1; B1 1 10, pAO-B1 with the silencer domain inserted upstream of 2 167; E1, pAO-E1; E1 1 10, pAO-E1 with the silencer domain inserted upstream of 2 167. (Bottom) Recom binant plasmids in either pGL3 or pAO-B1 or pASO-E1 parents were transfected into HC-11 cells along with pCMV-b -galactosidase. Luciferase activity was quantitated and normalized to b -galactosidase and protein concentration 48 h later.
the outcome of their joint participation in the expression of some genes (Apt et al., 1996) . On the other hand, the activation function of Sp3 could create a situation with Sp1 in which both proteins served as activators (Noti, 1997; Ihn and Trojanowska, 1997) . Complex combinatorial interactions between Sp1/Sp3 and TTF-1 or between Sp1/Sp3 and NF-1 or MZF-1 were found to be necessary for cell-type-specific activation of various genes (Toonen et al., 1996; Bohinski et al., 1994; Kida et al., 1999) . Whether related mechanisms operate in the hAOX promoter is at present unknown; however, the complex architecture of the hAOX upstream DNA suggests the possibility of novel interactions with Sp1/Sp3 in the proxim al prom oter.
The observation that the domain from 2 1978 to 2 2230 contains a silencer element may offer important insight into the mechanism of AOX expression and regulation. Although silencer elements regulate the expression of many different genes, a common function appears to be in the control of cell-or tissue-type-specific expression. Epithelial silencer function has been described for platelet-derived growth factor (Liu et al., 1996) , transferrin (Sawaya et al., 1996) , lipooxygenase (O'Prey and Harrison, 1995) , and fibroblast growth factor (Gelfm an et al., 1998) . It has been proposed that silencer elements stabilize interactions between upstream sequences and activator sites within a proximal promoter (Liu et al., 1996) . Cell-type-specific activation of the silencer element, perhaps through specific protein binding or effects on native chromatin structure, could thereby control activation from the proximal promoter. Several nuclear proteins have been reported to activate silencer elements, including Sp1 (Shou et al., 1998) , YY1 (Ye et al., 1996) , and Oct-1 (Kim et al., 1996) . However, the highly A:Trich nature of the hAOX silencer elem ent does not convincingly predict binding by any of these factors, and further localization of the hAOX silencer elem ent should clarify potential protein binding sites.
Our goals in the present analysis were to characterize features in the hAOX upstream DNA that could confer regulation of expression and to identify transcription factors that mediate activation. This information should allow us to identify regulatory mechanisms not previously recognized. Hence, the observation that Sp1/Sp3 are essential for activation in the proximal promoter is important, because these proteins can be activated by growth factors (Kim et al., 1996; Chen et al., 1998; Li et al., 1995; Greenwel et al., 1997) and by cytokines interleukin-1 and IL-6 (Ray et al., 1999) , and they mediate combinatorial interaction with other cell-specific factors (Braun and Suske, 1998) . Furthermore, the potential for interaction between the proximal promoter in hAOX and an upstream silencer element suggests complex regulatory mechanisms of expression.
